Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Damodaran S, et al. Among authors: deming da. J Clin Oncol. 2022 May 10;40(14):1552-1561. doi: 10.1200/JCO.21.01648. Epub 2022 Feb 8. J Clin Oncol. 2022. PMID: 35133871 Free PMC article. Clinical Trial.
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. Deming DA, et al. Invest New Drugs. 2014 Apr;32(2):323-9. doi: 10.1007/s10637-013-0035-8. Epub 2013 Oct 10. Invest New Drugs. 2014. PMID: 24114123 Free PMC article. Clinical Trial.
E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.
Lubner S, Feng Y, Mulcahy M, O'Dwyer P, Giang GY, Hinshaw JL, Deming D, Klein L, Teitelbaum U, Payne J, Engstrom P, Stella P, Meropol N, Benson A. Lubner S, et al. Oncologist. 2018 Sep;23(9):1006-e104. doi: 10.1634/theoncologist.2018-0294. Epub 2018 May 31. Oncologist. 2018. PMID: 29853660 Free PMC article.
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. Dasari A, et al. Among authors: deming da. Nat Rev Clin Oncol. 2020 Dec;17(12):757-770. doi: 10.1038/s41571-020-0392-0. Epub 2020 Jul 6. Nat Rev Clin Oncol. 2020. PMID: 32632268 Free PMC article. Review.
mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.
Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, Albrecht D, Washington MK, Sullivan R, Weichert JP, Halberg RB. Deming DA, et al. PLoS One. 2013 Apr 9;8(4):e60709. doi: 10.1371/journal.pone.0060709. Print 2013. PLoS One. 2013. PMID: 23593290 Free PMC article.
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G. Deming DA, et al. Invest New Drugs. 2016 Apr;34(2):168-75. doi: 10.1007/s10637-015-0314-7. Epub 2015 Dec 14. Invest New Drugs. 2016. PMID: 26666244 Free PMC article. Clinical Trial.
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.
Yueh AE, Payne SN, Leystra AA, Van De Hey DR, Foley TM, Pasch CA, Clipson L, Matkowskyj KA, Deming DA. Yueh AE, et al. Among authors: deming da. PLoS One. 2016 Feb 10;11(2):e0148730. doi: 10.1371/journal.pone.0148730. eCollection 2016. PLoS One. 2016. PMID: 26863299 Free PMC article.
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Morris VK, et al. Lancet Oncol. 2017 Apr;18(4):446-453. doi: 10.1016/S1470-2045(17)30104-3. Epub 2017 Feb 18. Lancet Oncol. 2017. PMID: 28223062 Free PMC article. Clinical Trial.
88 results